Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repros starts patient dosing in Phase 2 low-dose Proellex trial
The trial aims to assess the impact of the drug on menstrual events, as well as liver function. In the trial, the patients will be administered with 12mg
The trial aims to assess the impact of the drug on menstrual events, as well as liver function. In the trial, the patients will be administered with 12mg
TCN-032 was discovered utilizing Theraclone’s I-STAR platform. The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo. The study expects
The company has also opened an additional study and recruiting patients at the Stanford University Medical Center in Palo Alto, CA. The study aims to investigate safety and
In his new role, Adams will be responsible for strengthening the company’s R&D operations and commercial infrastructures to support NLX-P101. Prior to joining Neurologix, Adams worked as the
The agreement allows CMC Biologics to manufacture bulk IB1001, Inspiration’s intravenous recombinant factor IX (rFIX) product, for at least six years. Further details of the agreement were not
The earlier studies, which included previously untreated genotype-1 chronic HCV patients and the patients who failed previous treatment, showed improvements in cure rates when treated with telaprevir in
The deal includes a two-year research collaboration with Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development. Further, the financial
Burns has held executive management positions at Renishaw Diagnostics, Cyntellect, GE Healthcare, Imaging Research, BioSignal Packard, and Pharmacia / LKB. Cellectricon chairman Axel Broms said they are looking
NSF International and HFL Sport Science, the two independent sports testing laboratories, working on sports nutrition safety, have certified EAS quality processes and facilities and is expected to
Liovel is a fixed dose combination tablet of Nesina (alogliptin) and Actos (pioglitazone HCL). Nesina, which is a member of the dipeptidyl peptidase IV (DPP-4) inhibitor class, is